The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models
The use of anti-HER2 therapies has significantly improved clinical outcome in patients with HER2-positive breast cancer, yet a substantial proportion of patients acquire resistance after a period of treatment. The PI3K/AKT/mTOR pathway is a good target for drug development, due to its involvement in...
Main Authors: | Marta Sanz-Álvarez, Ester Martín-Aparicio, Melani Luque, Sandra Zazo, Javier Martínez-Useros, Pilar Eroles, Ana Rovira, Joan Albanell, Juan Madoz-Gúrpide, Federico Rojo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/11/2778 |
Similar Items
-
Regulation of mTORC1 by lysosomal calcium and calmodulin
by: Ruo-Jing Li, et al.
Published: (2016-10-01) -
Hyperactivity of mTORC1- and mTORC2-dependent signaling mediates epilepsy downstream of somatic PTEN loss
by: Erin R Cullen, et al.
Published: (2024-03-01) -
Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines
by: Marta Sanz-Álvarez, et al.
Published: (2023-12-01) -
Genetic inactivation of mTORC1 or mTORC2 in neurons reveals distinct functions in glutamatergic synaptic transmission
by: Matthew P McCabe, et al.
Published: (2020-03-01) -
mTORC1 signaling in hepatic lipid metabolism
by: Jinbo Han, et al.
Published: (2017-04-01)